Verastem, Inc. (VSTM): Results of Operations and Financial Condition
Verastem, Inc. (VSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622452d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 reg
How this was made
The 30-second read
Why it matters
Traders can update models for liquidity (cash, pro forma cash with Oberland), near-term catalysts (October clinical data, year-end enrollment completion), and commercial momentum (Q2 net product revenue $25.1M).
Market read
The filing combines financial reporting with concrete liquidity and clinical execution milestones, which can shift biotech risk pricing ahead of upcoming data.
What to watch
Key near-term risk is whether VS-7375 October data and mid-2027 RAMP 301 topline endpoint confirm differentiation; commercial revenue growth may be insufficient to offset burn without approvals.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering Verastem Oncology’s Q2 2026 financial results and business updates across its commercial product AVMAPKI/FAKZYNJA CO-PACK and pipeline asset VS-7375.
Ticker impact
Verastem reported Q2 2026 results, $25.1M AVMAPKI/FAKZYNJA CO-PACK revenue, and $90M incremental non-dilutive funding plus VS-7375 trial enrollment updates.
Near-term sentiment likely positive on runway clarity and ongoing trial enrollment progress, with follow-through tied to October clinical data expectations.
The filing discloses new financing terms (up to $75M, $50M at closing, pro forma cash $201.4M) and specific operational milestones (first patients dosed across three TARGET-D Phase 2 trials, enrollment expected by year-end), which can move biotech risk perception and liquidity expectations.
Market effects
Reinforces investor appetite for KRAS G12D targeted oncology programs and non-dilutive royalty financing structures in small-cap biotech.
Limited direct regional impact; includes Japan study update presentation details.
Global relevance mainly through multi-region clinical trial execution and expected October data readouts.
Counterpoint
Runway extension is helpful, but the stock still depends on future clinical efficacy and regulatory milestones; financing may not de-risk probability of success.
Key entities
- companyVerastem Oncology
Nasdaq-listed biopharmaceutical company filing Q2 2026 results and pipeline/commercial updates.
- drug_programVS-7375
Oral KRAS G12D (ON/OFF) inhibitor in advanced solid tumors; first patients dosed across three TARGET-D Phase 2 trials.
- productAVMAPKI/FAKZYNJA CO-PACK
Avutometinib capsules and defactinib tablets; generated $25.1M net product revenue in Q2 2026.
- financing_counterpartyOberland Capital
Provides non-dilutive royalty financing up to $75M, including $50M at closing.
- partnerErasca, Inc.
Intends to evaluate VS-7375 with ERAS-0015 in preclinical models, subject to definitive agreement.
